<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:9pt Arial, sans-serif; }
 .font2 { font:10pt Arial, sans-serif; }
 .font3 { font:21pt Arial, sans-serif; }
 .font4 { font:17pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font4">J.P. Morgan</span></p>
<p><span class="font0" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font1" style="font-weight:bold;">07 September 2016</span></p>
<p><span class="font1" style="font-weight:bold;">Isabella Y. Zhao, CFA</span></p>
<p><span class="font1" style="font-weight:bold;">(852) 2800-8534</span></p>
<p><a href="mailto:isabella.zhao@jpmorgan.com"><span class="font1" style="font-weight:bold;">isabella.zhao@jpmorgan.com</span></a></p><a name="caption1"></a>
<h3><a name="bookmark0"></a><span class="font3"><a name="bookmark1"></a>SWOT Analysis</span></h3>
<table border="1">
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Strengths</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Weaknesses</span></p></td></tr>
<tr><td style="vertical-align:top;">
<ul style="list-style:none;"><li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;It is the largest pharmaceutical distributor in China</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;Owned by the largest state owned pharmaceutical group, CNPGC and Shanghai Fosun Pharmaceuticals, a major private drug maker. This enhances credibility and stature of Sinopharm and can lead to greater access to hospitals</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;The company has the largest supply chain network covering 31 provinces and 241 logistics centers. Also, it owns the largest number of retail drug stores in major cities in China</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;The country’s largest portfolio to meet demand from customers and widest network coverage to satisfy the need of manufacturers to grow business nationwide</span></p></li></ul></td><td style="vertical-align:top;">
<ul style="list-style:none;"><li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;The nature of the business results in very low net margins (1.66%in 2015)</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;Limited presence in other Asian or Global markets</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;Healthcare expenditure as a % of GDP is low as compared to other developed markets</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;A large chunk of revenue comes from hospitals (62%). So any reform in hospital policies can damage revenue</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;The company is dependent on a number of key suppliers, all of whom may opt to use smaller distributors if they offer better terms</span></p></li></ul></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Opportunities</span></p></td><td style="vertical-align:middle;">
<p><span class="font1" style="font-weight:bold;">Threats</span></p></td></tr>
<tr><td style="vertical-align:top;">
<ul style="list-style:none;"><li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;E-commerce will pose as a new growth driver for traditional pharma firms with strong platforms and resources</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;Public hospital reform will lead to separation of treatment and drug sales, which in turn will bring enormous opportunities for drug retail business</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;China Sinopharm International Corporation will provide opportunities to expand the trade globally</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;Heightened interest in expanding drugstore business should lead to higher margins and cash flow in the longer term</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;Numerous M&amp;A opportunities in distribution industry with many small distributors that may be available at reasonable valuations</span></p></li></ul></td><td style="vertical-align:top;">
<ul style="list-style:none;"><li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;Huge competition from Chinese pharmaceutical retailers as a number of these local players are now listed</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;Global established players entering the market will further increase pressure</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;Pharmaceutical sales is a highly regulated industry with government imposed caps on drug prices</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;Though sector growth is more than Chinese GDP growth rate, it has slowed in recent years</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;Implementation risk of moving from developed Tier I cities to smaller cities and towns is quite significant</span></p></li>
<li>
<p><span class="font2">• &nbsp;&nbsp;&nbsp;Rising interest rates will drive up finance costs</span></p></li></ul></td></tr>
</table>
<p><span class="font0">Source: J.P. Morgan</span></p>
<p><span class="font1" style="font-weight:bold;">20</span></p>
</body>
</html>